about the product
Transparent or slightly opalescent, colorless or light yellow solution
Original product
This product is a fully original Promomed product
On every original product you will see our brand label
Specifications
Name
TROMBOPHORS® FORTE
Dosage form
SOLUTION FOR SUBCUTANEOUS ADMINISTRATION
Nosological classification
Antithrombotic agents
INN
CALCIUM NADROPARIN
Dosages
19000 anti-Xa IU/ml
ATC code
B01AB06
Active substance
Calcium Nadroparin
Pharmacotherapeutic group
General therapy drugs
use
For subcutaneous administration.
The drug THROMBOPHORS FORTE is not intended for intramuscular administration.
Clinical monitoring of platelet count should be performed during treatment with THROMBOPHORSE FORTE.
When performing spinal/epidural anesthesia/spinal puncture, it is also necessary to familiarize yourself with the information provided in the "Special instructions" section of the leaflet. Particular attention should be paid to specific instructions for use for each drug belonging to the class of low molecular weight heparins (NMH), as they may use different dosage units (units or mg). As a result, it is unacceptable to alternate the drug THROMBOPHORSE FORTE with other NMH during long-term treatment. It is also necessary to pay attention to which drug is used - THROMBOPHORSE, a solution for subcutaneous administration, 9500 anti-Xa IU/ ml or THROMBOPHORSE FORTE, a solution for subcutaneous administration, 19,000 anti-Xa IU/ml, because this affects the dosage regimen.
Subcutaneous injection technique
Preferably, the drug is administered in the patient's "lying down" position, into the subcutaneous tissue of the anterolateral or posterolateral surface of the abdominal wall, alternately from the right and left sides. Insertion into the thigh is allowed. The needle should be inserted perpendicular, not at an angle, into a pre-formed fold of skin, which must be held between thumb and forefinger until the end of the injection of the solution. Do not rub the injection site after injection.
In the treatment of thromboembolic conditions, in the absence of contraindications, it is necessary to start therapy with oral anticoagulants as early as possible. In the treatment of thromboembolism, nadroparin therapy should be continued until the targets of the international normalized ratio (INR) are reached. Recommended dosage regimen: subcutaneously 1 time a day for 10 days. The dose depends on the patient's body weight
Help
Package leaflet
Nadroparin is a low molecular weight heparin (NMH) obtained by depolymerization from standard heparin. It is a glycosaminoglycan with an average molecular weight of approximately 4,300 daltons. Nadroparin exhibits a high ability to bind to the plasma protein antithrombin III (AT III). This binding leads to accelerated inhibition of factor Xa, which is responsible for the high antithrombotic potential of nadroparin. Other mechanisms providing the antithrombotic effect of nadroparin include activation of tissue factor conversion inhibitor (TFPI), activation of fibrinolysis through direct release of tissue plasminogen activator from endothelial cells, and modification of blood rheological properties (reduction of blood viscosity and increase in membrane permeability of platelets and granulocytes).
Treatment of thrombosis and thromboembolism
SymptomsThe main clinical sign of overdose with subcutaneous or intravenous administration is bleeding. It is necessary to monitor the number of platelets and other parameters of the blood coagulation system. Minor bleeding does not require special therapy: it is usually sufficient to reduce or introduce a subsequent dose of THROMBOPHORSE FORTE later.
TreatmentIt is necessary to consider the appointment of protamine sulfate only in severe cases of overdose. Protamine sulfate has a pronounced neutralizing effect against the anticoagulant effects of heparin, however, some anti-Xa activity of nadroparin remains. 0.6 ml of protamine sulfate neutralizes about 950 anti-Xa IU of nadroparin. The dose of protamine sulfate is calculated taking into account the time elapsed after the administration of heparin, with
a possible reduction in the dose of the antidote
For more information about all possible adverse reactions and the frequency of their occurrence, see the instructions in the corresponding table.
- Hypersensitivity to nadroparin or any other component of the drug
- Thrombocytonitis with the use of calcium nadroparin in the anamnesis
- Signs of bleeding or an increased risk of bleeding associated with impaired hemostasis, with the exception of DIC syndrome not caused by heparin
- Organic lesions of organs with a tendency to bleeding (for example, acute gastric or duodenal ulcer)
- Intracranial hemorrhage
- Acute infectious endocarditis
- Severe renal insufficiency (creatinine clearance less than 30 ml/min).
- Injuries or surgical interventions on the brain and spinal cord or on the eyes.
- Children under 18 years of age (due to insufficient data)
Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
Organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro
In a place protected from light at a temperature not exceeding 30 ° C. Do not freeze. Keep out of reach of children.
2 years. Do not apply after the expiration date.
They are available on prescription.
There is no data on the effect of the drug THROMBOPHORSE FORTE on the ability to drive vehicles and mechanisms.
our partners
Where to buy
